MK-9470

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H32FN3O3
Molecular Weight	489.5811
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NC(=O)C(C)(C)OC1=NC=C(C)C=C1)[C@@H](CC2=CC=C(OCCF)C=C2)C3=CC=CC(=C3)C#N

InChI

InChIKey=XIYPJXKEMLKFMD-HFZDXXHNSA-N

InChI=1S/C29H32FN3O3/c1-20-8-13-27(32-19-20)36-29(3,4)28(34)33-21(2)26(24-7-5-6-23(16-24)18-31)17-22-9-11-25(12-10-22)35-15-14-30/h5-13,16,19,21,26H,14-15,17H2,1-4H3,(H,33,34)/t21-,26+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18077184 | https://www.ncbi.nlm.nih.gov/pubmed/18423778 | https://www.ncbi.nlm.nih.gov/pubmed/20033684

MK-9470 is a selective, high-affinity, an inverse agonist for the cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging. Despite its moderately high lipophilicity, MK9470 shows good brain uptake and a high percentage of specific binding in the monkey brain. Radiolabeled MK-9470 has been used in the clinical setting to support CB1 receptor drug development for measuring receptor occupancy, to investigate CB1 receptor variability with gender and normal aging.

Originator

Approval Year

PubMed

Title	Date	PubMed
Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET.	2008-02-15	18077184

Patents

Sample Use Guides

In Vivo Use Guide

10 mCi

Route of Administration: Intravenous

Name

Type

Language

MK-9470

Common Name

English

PROPANAMIDE, N-((1S,2S)-2-(3-CYANOPHENYL)-3-(4-(2-FLUOROETHOXY)PHENYL)-1-METHYLPROPYL)-2-METHYL-2-((5-METHYL-2-PYRIDINYL)OXY)-

Preferred Name

English

Code System Code Type Description

EPA CompTox

DTXSID00241592